180 related articles for article (PubMed ID: 28471657)
1. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Kamada Y; Sakai N; Sogabe S; Ida K; Oki H; Sakamoto K; Lane W; Snell G; Iida M; Imaeda Y; Sakamoto J; Matsui J
J Med Chem; 2017 May; 60(10):4358-4368. PubMed ID: 28471657
[TBL] [Abstract][Full Text] [Related]
2. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
3. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
McCoull W; Abrams RD; Anderson E; Blades K; Barton P; Box M; Burgess J; Byth K; Cao Q; Chuaqui C; Carbajo RJ; Cheung T; Code E; Ferguson AD; Fillery S; Fuller NO; Gangl E; Gao N; Grist M; Hargreaves D; Howard MR; Hu J; Kemmitt PD; Nelson JE; O'Connell N; Prince DB; Raubo P; Rawlins PB; Robb GR; Shi J; Waring MJ; Whittaker D; Wylot M; Zhu X
J Med Chem; 2017 May; 60(10):4386-4402. PubMed ID: 28485934
[TBL] [Abstract][Full Text] [Related]
5. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
[TBL] [Abstract][Full Text] [Related]
6. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
7. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship.
Sakamoto K; Sogabe S; Kamada Y; Sakai N; Asano K; Yoshimatsu M; Ida K; Imaeda Y; Sakamoto JI
Biochem Biophys Res Commun; 2017 Jan; 482(2):310-316. PubMed ID: 27856253
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Yasui T; Yamamoto T; Sakai N; Asano K; Takai T; Yoshitomi Y; Davis M; Takagi T; Sakamoto K; Sogabe S; Kamada Y; Lane W; Snell G; Iwata M; Goto M; Inooka H; Sakamoto JI; Nakada Y; Imaeda Y
Bioorg Med Chem; 2017 Sep; 25(17):4876-4886. PubMed ID: 28760529
[TBL] [Abstract][Full Text] [Related]
9. A novel small-molecule PPI inhibitor targeting integrin αvβ3-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice.
Park D; Park CW; Choi Y; Lin J; Seo DH; Kim HS; Lee SY; Kang IC
Biomaterials; 2016 Aug; 98():131-42. PubMed ID: 27187277
[TBL] [Abstract][Full Text] [Related]
10. Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.
Pierrat OA; Liu M; Collie GW; Shetty K; Rodrigues MJ; Le Bihan YV; Gunnell EA; McAndrew PC; Stubbs M; Rowlands MG; Yahya N; Shehu E; Talbot R; Pickard L; Bellenie BR; Cheung KJ; Drouin L; Innocenti P; Woodward H; Davis OA; Lloyd MG; Varela A; Huckvale R; Broccatelli F; Carter M; Galiwango D; Hayes A; Raynaud FI; Bryant C; Whittaker S; Rossanese OW; Hoelder S; Burke R; van Montfort RLM
Sci Rep; 2022 Nov; 12(1):18633. PubMed ID: 36329085
[TBL] [Abstract][Full Text] [Related]
11. In silico structure-based approaches to discover protein-protein interaction-targeting drugs.
Shin WH; Christoffer CW; Kihara D
Methods; 2017 Dec; 131():22-32. PubMed ID: 28802714
[TBL] [Abstract][Full Text] [Related]
12. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
13. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
14. Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors.
Sable R; Jois S
Molecules; 2015 Jun; 20(6):11569-603. PubMed ID: 26111183
[TBL] [Abstract][Full Text] [Related]
15. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
[TBL] [Abstract][Full Text] [Related]
16. Ligand efficiency based approach for efficient virtual screening of compound libraries.
Ke YY; Coumar MS; Shiao HY; Wang WC; Chen CW; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Chang CM; Hsieh HP
Eur J Med Chem; 2014 Aug; 83():226-35. PubMed ID: 24960626
[TBL] [Abstract][Full Text] [Related]
17. Identification of Inhibitors for the Lutheran Blood Group Glycoprotein - Laminin 511/521 Interaction by Molecular Modelling and Simulation Techniques.
Madeleine N; Gardebien F
Curr Comput Aided Drug Des; 2018; 14(3):253-268. PubMed ID: 27439722
[TBL] [Abstract][Full Text] [Related]
18. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
[TBL] [Abstract][Full Text] [Related]
19. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
20. Surface Plasmon Resonance: A Useful Strategy for the Identification of Small Molecule Argonaute 2 Protein Binders.
Poser E; Genovese I; Masciarelli S; Bellissimo T; Fazi F; Colotti G
Methods Mol Biol; 2017; 1517():223-237. PubMed ID: 27924486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]